KUALA LUMPUR (Reuters) – Malaysia Pharmaniaga Bhd has signed an agreement with China’s Sinovac to purchase ready-to-fill COVID-19 vaccines and later to manufacture the vaccine domestically, it said on Tuesday.
Pharmaniaga said in a filing to the bourse that the company will carry out a fill-and-finish process of the vaccine in Malaysia, and will subsequently enter into local manufacturing, under license from Sinovac for its technology and know-how.
“This will also help Pharmaniaga in long-term partnerships, including technology transfer to grow the sector in Malaysia,” the company said.
Malaysia has been in talks to secure a total of 23.9 million doses of COVID-19 vaccines from Sinovac and another Chinese manufacturer CanSino Biologics, and from Russia’s Gamaleya Institute, the maker of the Sputnik V vaccine.
The Southeast Asian nation has also procured coronavirus vaccines from U.S. and German drugmakers Pfizer and BioNTech, as well as British-Swedish biopharmaceutical firm AstraZeneca PLC.
(Reporting by Liz Lee; Editing by Raju Gopalakrishnan)
